Side effects

18 June, 2025

The IIS Aragón and the Ibercaja Foundation have signed an agreement to promote the innovative oncology research project "Sara."

This research, led by the Molecular Oncology Group at the IIS Aragón, aims to improve the efficacy of chemotherapy while significantly reducing its adverse effects. The signing of this agreement reinforces the commitment of both institutions to the advancement of cancer research in Aragon.